Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease

BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease. METHODS: We present a series of four cases in which administration of ritux...

Descripción completa

Detalles Bibliográficos
Autores principales: León Román, Francisco, Pintado-Cort, Beatriz, García-Casado, Diana, Muñiz-González, Francisco, López García-Asenjo, José Antonio, Díaz-Rodríguez, Cristina, Montoro-López, María Nieves, Loucel-Bellino, Mauricio, Recio-Moreno, Beatriz, Rebollo-Garrido, Sara, Martínez-Hernández, Yaiza, Cusacovich, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Connective Tissue Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496654/
https://www.ncbi.nlm.nih.gov/pubmed/37673443
http://dx.doi.org/10.1136/rmdopen-2023-003479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496654/
https://www.ncbi.nlm.nih.gov/pubmed/37673443
http://dx.doi.org/10.1136/rmdopen-2023-003479

Ejemplares similares